Recurrent Platinum-Resistant Ovarian Carcinoma

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy